Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Communications Biology|November 18, 2021
Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancerAditi Gupta, Sadna Budhu, Kelly Fitzgerald, et al.Cancers|June 10, 2022
Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal MelanomaLukas Kraehenbuehl, Aliya Holland, Emma Armstrong, et al.Frontiers in Oncology|July 3, 2024
Comparative study of immune response to local tumor destruction modalities in a murine breast cancer modelSadna Budhu, Kwanghee Kim, Wesley Yip, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2022
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid TumorsDiwakar Davar, Roberta Zappasodi, Hong Wang, et al.Biorxiv : the Preprint Server for Biology|June 4, 2025
Mechanoimmunological Control of Metastatic Site SelectionYassmin A Elbanna, Maria Tello-Lafoz, Aliya Holland, et al.Journal for Immunotherapy of Cancer|June 7, 2020
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trialDmitriy Zamarin, Sven Walderich, Aliya Holland, et al.The Journal of Clinical Investigation|September 15, 2022
Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockadeArnab Ghosh, Judith Michels, Riccardo Mezzadra, et al.Nature Medicine|April 23, 2024
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analysesClaire F Friedman, Beryl L Manning-Geist, Qin Zhou, et al.Nature Communications|September 9, 2022
In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy responseAditi Sahu, Kivanc Kose, Lukas Kraehenbuehl, et al.Cell|March 31, 2023
T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variantsDaniel Hirschhorn, Sadna Budhu, Lukas Kraehenbuehl, et al.Pageof 2